Health Condition 1: N185- Chronic kidney disease, stage 5
Conditions
Interventions
Control Intervention1: Nil: NIL
Sponsors
J Gangadhar Naik
Eligibility
Inclusion criteria
Inclusion criteria: Only Haemodialysis Patients Patients aged only above 18 years Patients who are willing to participate in this study. Ability to speak and understand English or Kannada language Being conscious and cooperative
Exclusion criteria
Exclusion criteria: Patients on haemodialysis for ARF (Acute Renal Failure) Patients not willing to give consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall understanding of various drugs used in the management of CKD, its complications and other comorbid diseases associated with it, will help the clinical pharmacists, physicians in better management of patients, as far as adverse effects, costs, toxicities etc., of the drugs concerned. Thereby improving patient compliance to therapy and overall outcome of CKD pharmacotherapy. Timepoint: One year | — |
Secondary
| Measure | Time frame |
|---|---|
| A thorough understanding about healthcare schemes with their benefits which would help Hemodialysis patients to make an informed choice before opting for a scheme.Timepoint: 6 months;Cost-effective model would help not only physicians but also patientsâ?? hemodialysis patients in choosing a therapeutic option.Timepoint: 6 months;May improve the nutritional status, knowledge and skills of the haemodialysis patients toward their disease and dietary management due to nutrition education program.Timepoint: one year | — |
Countries
India
Contacts
Public ContactJ Gangadhar Naik
Manipal College of Pharmaceutical Sciences, MAHE, Manipal.
Outcome results
None listed